Journal of Headache and Pain

Article	Citations
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019	361
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates	245
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update	142
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy	126
A prospective real-world analysis of erenumab in refractory chronic migraine	122
European headache federation consensus on the definition of resistant and refractory migraine	121
Headache characteristics in COVID-19 pandemic-a survey study	105
Migraine and neuroinflammation: the inflammasome perspective	98
Migraine and sleep disorders: a systematic review	97
Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study	97
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience	88
Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study	84
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)	82
The fifth cranial nerve in headaches	80
Comorbidities of primary headache disorders: a literature review with meta-analysis	78
Lasmiditan mechanism of action – review of a selective 5-HT1F agonist	73
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study	72
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence	67
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs	66
Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials	63
From transformation to chronification of migraine: pathophysiological and clinical aspects	62
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace	60
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) stu	59
Long COVID headache	57
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects	57

Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy	55
Headache medication and the COVID-19 pandemic	50
Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study	49
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism	49
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine	47
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months	46
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)	45
Applying a biopsychosocial model to migraine: rationale and clinical implications	44
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis	43
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study	39
Association between response to triptans and response to erenumab: real-life data	39
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance	39
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis	39
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	38
Medication overuse and drug addiction: a narrative review from addiction perspective	36
Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence	36
Migraine, obesity and body fat distribution – a population-based study	36
The neuro-pathophysiology of temporomandibular disorders-related pain: a systematic review of structural and functional MRI studies	35
Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study	33
Differential alteration of fMRI signal variability in the ascending trigeminal somatosensory and pain modulatory pathways in migraine	33
Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients	33
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	32
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension	32
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine	31
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes	31
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region	31
Efficacy and safety of erenumab in women with a history of menstrual migraine	31
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	30
A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication	30
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	30
Is there a causal relationship between stress and migraine? Current evidence and implications for management	29
Inflammatory complications of CGRP monoclonal antibodies: a case series	29
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention	29
Impaired effective functional connectivity of the sensorimotor network in interictal episodic migraineurs without aura	28
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis	28
Immunogenicity of biologic therapies for migraine: a review of current evidence	28
Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?	28
Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine	28
OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients	28
Disrupted functional connectivity between sub-regions in the sensorimotor areas and cortex in migraine without aura	27
Concurrent brain structural and functional alterations in patients with migraine without aura: an fMRI study	27
Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury	26
Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020	26
Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis	26
Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period	26
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	25
Validation of an algorithm for automated classification of migraine and tension-type headache attacks in an electronic headache diary	25
Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension	25
Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study	25
Genetics of migraine aura: an update	25

Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice	25
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i	24
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA	24
European Headache Federation recommendations for placebo and nocebo terminology	24
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine	23
Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey	23
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation	23
Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions	23
Altered levels of salivary and plasma pain related markers in temporomandibular disorders	22
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure	22
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials	22
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study	22
Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid	22
Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data	22
Brain morphologic abnormalities in migraine patients: an observational study	21
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine	21
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy	21
The prevalence of headache disorders in children and adolescents in Lithuania: a schools-based study	21
Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia	20
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension	20
Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway	20
The prevalence of headache disorders in children and adolescents in Ethiopia: a schools-based study	20
Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE2	20
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study	20
Pitfals in recognition and management of trigeminal neuralgia	19
Modulation of mechanosensory vibrissal responses in the trigeminocervical complex by stimulation of the greater occipital nerve in a rat model of trigeminal neuropathic pain	19
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study	19
21st century headache: mapping new territory	19
Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities	19
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study	19
Clinical correlates of insomnia in patients with persistent post-traumatic headache compared with migraine	19
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures	19
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	19
Cognitive aging in migraine sufferers is associated with more subjective complaints but similar age-related decline: a 5-year longitudinal study	18
The role of deficient pain modulatory systems in the development of persistent post-traumatic headaches following mild traumatic brain injury: an exploratory longitudinal study	18
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology	18
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study	18
Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea	18
The prevalence of headache disorders in children and adolescents in Mongolia: a nationwide schools-based study	18
FKN/CX3CR1 axis facilitates migraine-Like behaviour by activating thalamic-cortical network microglia in status epilepticus model rats	18
Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database	18
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine	18
Gray and white matter abnormalities in primary trigeminal neuralgia with and without neurovascular compression	18
Prevalence of familial cluster headache: a systematic review and meta-analysis	18
Haemodynamic activity characterization of resting state networks by fractal analysis and thalamocortical morphofunctional integrity in chronic migraine	18
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana	17
Brain barriers and their potential role in migraine pathophysiology	17
Demoralization predicts suicidality in patients with cluster headache	17
Functional connectivity of the visual cortex differentiates anxiety comorbidity from episodic migraineurs without aura	17
Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre	17
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial	17
Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire	17
Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization	17
Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study	17
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience	17
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis	17
Patients with chronic migraine without history of medication overuse are characterized by a peculiar white matter fiber bundle profile	17
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience	17
The Global Campaign turns 18: a brief review of its activities and achievements	17
Assessment of normalized cerebral blood flow and its connectivity with migraines without aura during interictal periods by arterial spin labeling	17
Altered hypothalamic functional connectivity in post-traumatic headache after mild traumatic brain injury	16
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients	16
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany	16
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database	16
The status and high risk factors of severe psychological distress in migraine patients during nCOV-2019 outbreak in Southwest China: a cross-sectional study	16
Pain rates in general population for the period 1991–2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis	16
Exploring alterations in sensory pathways in migraine	15
A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan	15
Altered brain functional network dynamics in classic trigeminal neuralgia: a resting-state functional magnetic resonance imaging study	15
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway	15
Addressing chronic persistent headaches after MTBI as a neuropathic pain state	15
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis	15
A cross-sectional study on the burden and impact of migraine on work productivity and quality of life in selected workplaces in the Philippines	15
Whole-brain morphological alterations associated with trigeminal neuralgia	15
The patients’ perspective on the burden of idiopathic intracranial hypertension	15
Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence	15
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials	15
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience	15
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN tr	14
A universal outcome measure for headache treatments, care-delivery systems and economic analysis	14

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study	14
Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies	14
Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine	14
A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine	14
Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model	14
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies	14
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model	14
The chronobiology of migraine: a systematic review	14
The impact of remission and coexisting migraine on anxiety and depression in cluster headache	14
Burden of illness of trigeminal neuralgia among patients managed in a specialist center in England	14
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch	14
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	14
Cerebral perfusion variance in new daily persistent headache and chronic migraine: an arterial spin-labeled MR imaging study	14
Short-latency afferent inhibition and somato-sensory evoked potentials during the migraine cycle: surrogate markers of a cycling cholinergic thalamo-cortical drive?	13
Aberrant cerebral blood flow in tinnitus patients with migraine: a perfusion functional MRI study	13
Mild traumatic brain injury is associated with effect of inflammation on structural changes of default mode network in those developing chronic pain	13
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials	13
Phenome-wide analysis highlights putative causal relationships between self-reported migraine and other complex traits	13
Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine	13
Flatness of the Meckel cave may cause primary trigeminal neuralgia: a radiomics-based study	13
Metabotropic glutamate receptor 5 regulates synaptic plasticity in a chronic migraine rat model through the PKC/NR2B signal	13
Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis	13
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies	13
Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults	13
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials	13
Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series	13
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	13
The economic and personal burden of cluster headache: a controlled cross-sectional study	13
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine	13
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study	13
P2X7 receptors exert a permissive effect on the activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve terminals	12
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings	12
Thalamo-cortical networks in subtypes of migraine with aura patients	12
The bidirectional temporal relationship between headache and affective disorders: longitudinal data from the HUNT studies	12
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report	12
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model	12
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study	12
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)	12
Functional connectivity and structural changes of thalamic subregions in episodic migraine	12
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study	12
Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels	12
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients	12
Early alterations of cortical thickness and gyrification in migraine without aura: a retrospective MRI study in pediatric patients	12
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials	12
The relationship between headache-attributed disability and lost productivity: 1. A review of the literature	12
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study	12
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine	12
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study	12
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	11
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	11
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms	11
High concurrent validity between digital and analogue algometers to measure pressure pain thresholds in healthy participants and people with migraine: a cross-sectional study	11
Microstructural changes in the trigeminal nerve of patients with episodic migraine assessed using magnetic resonance imaging	11
Post-reversible cerebral vasoconstriction syndrome headache	11
Debate: Are cluster headache and migraine distinct headache disorders?	11
Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors	11
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials	11
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments	11
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab	11
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients	11
Subdiagnosis, but not presence of vestibular symptoms, predicts balance impairment in migraine patients – a cross sectional study	11
The International Headache Congress – IHS and EHF joint congress 2021	11
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms	11
Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress	11
My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland	11
What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials	11
Sentinel headache as a warning symptom of ischemic stroke	11
On the utility of the trail making test in migraine with and without aura: a meta-analysis	11
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial	11